


A**B**

Treatment	<i>n</i>	Median survival (days)	p-value (no treatment)	p-value (null genome)	p-value (2011A)
IT AAV9.trastuzumab	6	111	0.0012	0.0069	0.0027
IT AAV9.2011A	10	54.5	0.0960	0.2889	-
IT AAV9.null	4	50	0.0786	-	-
IT PBS	8	48.5	-	-	-

Supplemental Figure 1. IT AAV9.trastuzumab tumor prophylaxis pilot experiment. (A) Kaplan-Meier survival curves for mice that received IT AAV9.trastuzumab tumor prophylaxis, IT AAV9.2011A, AAV9.null genome, or IT PBS at least 21 days before tumor challenge. (B) Tabulated survival and statistical data for Fig. 1A. The survival of the three control groups is statistically the same, while the AAV9.trastuzumab group survived significantly longer.